Appendix Table C62. Study withdrawals and adverse events (outcomes part D), ACEI plus aldosterone antagonist versus. ACEI plus placebo trials

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Any Study Withdrawals,**  **n/N (%)** | | **Withdrawals Due to Serious Adverse Event, n/N (%)** | | **Serious Adverse Event: Any, n/N (%)** | | **Adverse Event:**  **Any, n/N (%)** | | **Adverse Event, Specific, n/N (%)** | | **Renal Adverse Event, n/N (%)** | |
| **ACEI + Aldo Antag** | **ACEI + Placebo** | **ACEI + Aldo Antag** | **ACEI + Placebo** | **ACEI + Aldo Antag** | **ACEI + Placebo** | **ACEI + Aldo Antag** | **ACEI + Placebo** | **ACEi + Aldo Antag** | **ACEI + Placebo** | **ACEI + Aldo Antag** | **ACEI + Placebo** |
| Mehdi, 200945 | 10/27 (37.0) | 6/27 (22.2) | \*NR | \*NR |  |  |  |  | HyperK: 2/27 (7.4) | HyperK: 0/27 |  |  |

ACEI = angiotensin converting enzyme inhibitor; HyperK = hyperkalemia; Aldo Antag = aldosterone antagonist  
\*Study reported withdrawals due to adverse events, but not specifically due to serious adverse events: ACEI + Aldo Antag (2 hyperkalemia, 2 stroke, 1 hypotension, 1 increased serum creatinine, 1 gynecomastia) and ACEI + placebo (1 stroke, 1 increased serum creatinine).